---
title: Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical
  practice
date: '2024-06-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38843478/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240607181525&v=2.18.0.post9+e462414
source: Blood
description: Fostamatinib, a recently approved syk inhibitor used in adult primary
  immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder.
  However, clinical trial results may not be similarly reproduced in clinical practice.
  Here 138 ITP patients (both primary and secondary) from 42 Spanish centers who had
  been treated with fostamatinib were evaluated prospectively and retrospectively.
  The median age of our cohort (55.8% women) was 66 years (interquartile range, IQR,
  ...
disable_comments: true
---
Fostamatinib, a recently approved syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here 138 ITP patients (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range, IQR, ...